Dieter Bielang Joins Sapheon As International Sales Director, Europe
SANTA ROSA, Calif.--(BUSINESS WIRE)--Apr 3, 2012-- Sapheon Inc.
announced today that Dieter Bielang has joined the company in the position of International Sales Director, Europe. Dieter comes to Sapheon from his position as Vice President, Vascular Interventions at Covidien (VNUS). He was responsible since 2003 for launching and establishing a dominant market position for the VNUS RF System in Europe and elsewhere outside the United States. Previously, Dieter held direct sales and distribution channel management positions with a number of successful startup companies. He brings more than 30 years' experience and leadership in the European medical device industry to Sapheon.
"I am very excited about this opportunity to introduce a compelling new technology to physicians and patients throughout Europe," Mr.
Bielang stated. "The VenaSeal(TM) Sapheon Closure System represents an unmatched improvement over older ablation therapies. I am fortunate to be associated with a significant advancement in the treatment of saphenous vein disease." "Dieter has long been at the forefront of bringing new medical device technologies to markets in Europe," said Gary McCord, Vice President, New Business Development, Sapheon Inc. "His acceptance of this position with our young company is a powerful testament to Sapheon's potential to quickly become a market leader." The VenaSeal(TM) Sapheon Closure System is a CE Mark approved advanced proprietary medical adhesive and single-use, catheter-based delivery system that enables immediate and permanent closure of the saphenous vein without surgery, thermal ablation, or sclerosing chemicals.
Patients treated with the VenaSeal(TM) Sapheon Closure System avoid significant post procedure pain and bruising and can immediately resume normal lifestyle activities. The VenaSeal(TM) Sapheon Closure System is not available for sale in the United States.
About Sapheon Sapheon is an early stage medical device company whose mission is to develop new approaches for the treatment of vascular disease. Please visit www.sapheoninc.com to learn more about our business.
CONTACT: Sapheon Inc.
Harry Phillips, 707-206-6820 email@example.com KEYWORD: UNITED STATES EUROPE NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: WOMEN SURGERY HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES MEDICAL DEVICES RADIOLOGY OTHER HEALTH FDA CONSUMER GENERAL HEALTH MEN SOURCE: Sapheon Inc.
Copyright Business Wire 2012 PUB: 04/03/2012 05:36 PM/DISC: 04/03/2012 05:36 PM http://www.businesswire.com/news/home/20120403006978/